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Introduction
The liver (the largest organ of the human body) is 
considered as a gland capable of performing endocrine-
metabolic and exocrine functions (1-3). The liver plays a 
key role in the homeostasis of the whole body metabolism. 
In particular, synthesizing many proteins and enzymes, the 
liver plays a primary role in the regulation of the energetic 
metabolism and it also contributes to the detoxification 
and elimination of a wide variety of both endogenous 
and exogenous molecules. In addition, the liver secretes 
bile that is necessary for the digestion of fats. The bile is 
then delivered to the second portion of the duodenum 
through intrahepatic bile ducts (4), whose lumen is lined by 
specialized epithelial cells: cholangiocytes (5,6) that modify 
the final composition of bile by a number of basal and 
hormone-regulated events (4,5,7,8).
Features of the biliary tree
The human biliary tree originates at the level of the biliary 
pole of hepatocytes that are responsible for the production 
of canalicular bile (9). Thereafter, the bile is secreted into 
the lumen of bile canalicular. The bile canalicular are narrow 
spaces of 0.5-2 μm delimited by simple introflections of the 
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plasma membrane at the biliary poles of adjacent hepatocytes. 
The biliary pole of hepatocytes is characterized by numerous 
and short microvilli that protrude into the lumen and, it is 
isolated from the vascular pole by occluding junctions (10).
Near the biliary pole, the cytoskeleton of hepatocytes 
is characterized by many microfilaments predominantly 
formed by actin and myosin. These microfilaments that are 
located around the bile canalicular regulates the passage 
of bile along the canals themselves. The canals of Hering 
origin in proximity of portal spaces (10,11).
The point at which the bile canalicular continue into 
the canals of Hering is defined as the ductule-canalicular 
junction. At this level, intrahepatic bile ducts are partly lined 
by cholangiocytes and in part by hepatocytes. At this point 
of the biliary epithelium, partially undifferentiated cells have 
been identified: the hepatic progenitor cells (HPC) (12). 
HPC constitute a resident stem cell compartment in the 
liver and they are able to differentiate into both hepatocytes 
and cholangiocytes (13-15). The canals of Hering are, 
therefore, points of anatomical and physiological connection 
between the bile canalicular and interlobular bile ducts in 
the portal space. The canals of Hering are lined by a few 
(3 or 4) cubic-shaped cholangiocytes, which rest on a thin 
basement membrane (7,16). The canals of Hering continue 
into the interlobular ducts, lined by a continuous layer of 
cylindrical-shaped cholangiocytes (16). The interlobular 
ducts are characterized by a diameter of 15-100 μm and in 
the portal space they draw up alongside the ramifications of 
the hepatic artery and of the portal vein. The interlobular 
bile ducts then continue into ducts of progressively larger 
size to form two large intrahepatic ducts (right and left 
hepatic duct), which drain respectively the right and left 
hepatic lobe of the liver and, at the hilum, they give rise to 
the extrahepatic bile ducts (4,17,18).
According to diameter the human intrahepatic bile 
duct can be classified into: large ducts (>800 μm), and then 
gradually segmental ducts, zonal, septal, interlobular ducts 
(15-100 μm) and ductules (<15 μm) (16).
In rodents, the intrahepatic biliary ductal system is 
morphologically heterogeneous and is formed by small 
(<15 μm of diameter, lined by small cholangiocytes, 8 μm 
in size) and large (>15 μm of diameter, lined by large 
cholangiocytes, 15 μm in size) bile ducts (5,7).
Vascularization and innervation of the biliary tree
The biliary epithelium is nourished by terminal branches 
of the hepatic artery, which constitute a complex vascular 
system called the peribiliary plexus (PBP). The PBP, which 
extends up to the interlobular ducts flows into the hepatic 
sinusoids, either directly through lobular branches, which 
indirectly through branches of the portal vein or pre-
lobular branches (17,19,20). In addition, numerous studies 
performed on rats have shown that small and large bile 
ducts have a different vascularization (21). In fact, the 
PBP is more extended in large bile ducts. The resulting 
difference of blood supply strongly influences the metabolic 
capabilities and functions of bile ducts of different size and 
of cholangiocytes that line their walls (17,22). The PBP is 
characterized by a bilaminar vascular network near the hilus 
of the liver and larger portal tracts, whereas it is formed by 
fewer connected vessels in the smaller portal tracts (23).
From a physiological point of view, the PBP is crucial 
in allowing the active reabsorption and therefore the 
modification of bile by cholangiocytes. In particular, it allows 
to reabsorb substances present in the bile and to bring them 
back to parenchymal cells (17). The canals of Hering and 
part of bile ductules are not directly vascularized (23), and 
this could in part justify the quiescent state under normal 
conditions of the HPC compartment located in this tract of 
the biliary tree (23).
The human intra- and extra-hepatic biliary epithelium 
is innervated by autonomic nerves that originate from 
the celiac plexus (sympathetic fibers) and the vagus nerve 
(parasympathetic fibers). These nerve fibers are organized 
to form the hepatic plexus divided into: anterior plexus 
around the hepatic artery and posterior plexus surrounding 
portal vein and bile duct (24).
Hepatic plexus (anterior and posterior) nerve fibers that 
originate through the hilum penetrate the liver parenchyma 
following the branches of the hepatic artery, the portal vein 
and the biliary tree. This innervation is also extended to 
hepatocytes and intrahepatic vascular structures (19,25).
In addition to classical neurotransmitters (e.g., 
adrenaline, noradrenaline and acetylcholine), the nerve 
fibers release in the liver numerous other neuropeptides 
such as neuropeptide Y (NPY), the calcitonin gene-
related peptide (CGRP), somatostatin, vasoactive intestinal 
polypeptide (VIP), enkephalin and bombesin. Many of these 
neuropeptides have been shown to be able to stimulate or 
inhibit the functional activity of cholangiocytes (26,27).
Experimental models for the study of biliary tree 
and cholangiocytes
In both rat and human livers, cholangiocytes are heterogeneous 
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in size (that can vary from 3 to 80 μm2) (7) and line bile ducts 
of different sizes (5,7). For example, intrahepatic bile ducts of 
small dimensions (small bile ducts: diameter less than 15 μm) (5) 
are lined by cholangiocytes of smaller size, whose diameter 
is about 8 μm (small cholangiocytes) (7). In contrast, bile 
ducts of greater size (large bile ducts: diameter greater than 
15 μm) are lined by cholangiocytes more voluminous, whose 
diameter is around 15 μm (large cholangiocytes) (7,18). In 
addition to morphological heterogeneity, cholangiocytes 
display ultrastructural, antigenic, functional and proliferative 
heterogeneous responses (7,10,18,28). In fact, small 
cholangiocytes possess cuboidal shape and have a larger 
nucleus and scant cytoplasm (10). This aspect is typical 
of poorly differentiated cells in which it occurs an intense 
synthesis of RNA messenger but lower post-transcriptional 
activity. Conversely, large cholangiocytes have columnar 
shape, a small nucleus and abundant cytoplasm (7,18). Both 
small and large cholangiocytes express cytokeratin-7 and -19, 
alkaline phosphatase, whereas only large cholangiocytes the 
secretin receptor, cystic fibrosis transmembrane conductance 
regulator (CFTR) and chloride bicarbonate anion exchanger 
2 (Cl-/HCO-3 AE2) and respond to secretin with enhanced 
secretory and proliferative activities (2,5,7,29-31). 
A number of experimental models have improved our 
understand of the mechanisms that regulate cholangiocytes 
proliferation, apoptosis, secretion, transport, signal 
transduction and the corresponding dysfunctions that 
lead to the diseases of the biliary tract. Three types of 
cholangiocytes proliferation have been described (27). 
Type I or “typical” cholangiocyte proliferation: represents 
a hyperplastic reaction that involves an increase of the 
number of intrahepatic bile ducts, confined to the portal 
space. Cholangiocytes proliferating, form well-differentiated 
tubular structures that show a well-defined lumen (4,13). In 
rodents, “typical” cholangiocyte proliferation is observed 
in different experimental conditions such as extrahepatic 
bile duct ligation (BDL) (2,4,22), partial hepatectomy (32) 
and chronic treatment with L-proline (33). In addition, 
“typical” cholangiocytes proliferation is also observed after 
the acute administration of carbon tetrachloride (CCl4) (34) 
or chronic feeding α-naphthylisothiocyanate (ANIT) (35) 
or bile salts such as Taurocholate (36,37). In human liver, a 
typical cholangiocyte proliferation is observed during acute 
obstructive cholestasis and in the early stages of chronic 
cholestatic diseases. This type of proliferation appears to be 
due to the stretching of the existing bile ducts localized in 
the portal tracts (27,38).
Type II or “atypical” proliferation occurs in rodents after 
the administration of CCl4 (39) and it is present in humans 
after massive hepatic necrosis, alcoholic liver disease, focal 
nodular hyperplasia and chronic cholestatic diseases such 
as primary biliary cirrhosis (PBC) and PSC (27,40). This 
pathology is characterized by the proliferation of intrahepatic 
bile ducts not confined to portal areas but extended to the 
periportal area and in the adjacent liver parenchyma. This 
type of proliferation leads to the formation of irregular 
and tortuous ductular structures that do not possess a well-
defined lumen and are associated with inflammation and 
infiltration of neutrophils; moreover, these neo-formed ducts 
are not functionally efficient. Unlike “typical” proliferation, 
in type II proliferation has been described the presence of 
transitional cells with phenotypic characteristics of both 
cholangiocytes and hepatocytes. This finding is in favor of 
the hypothesis that atypical proliferation is a phenomenon 
of metaplasia and may originate from the hepatic progenitor 
cell compartment rather than from the replication of pre-
existing ducts (13,27).
Type III proliferation (“oval cell” proliferation) 
characterizes the early stages of carcinogenesis in rat liver 
and is caused by treatment with chemicals. This pathology 
is characterized by the formation of tubular irregular and 
disorganized structures with a not well defined lumen which 
protrude inside the hepatic lobule with alteration of the 
architecture of the entire parenchyma (27).
Oval cells, so called for their shape, represent a 
subpopulation of cells, located at levels of canals of Hering that 
are heterogeneous in the expression of proteins and cell surface 
markers (13,41-43). Oval cells show phenotypes of immature 
or neoplastic hepatocytes (e.g., expression of α-fetoprotein and 
albumin) and cholangiocytes (e.g., expression of cytokeratin 7 
and 19) (41,44). Oval cells have the capability of differentiating 
into hepatocytes, cholangiocytes, enterocytes, and exocrine 
pancreatic cells (42,43).
BDL is the most used experimental model to study 
“typical” proliferation of cholangiocytes. This maneuver 
causes a rapid and marked proliferation of bile ducts leading 
to increased biliary mass (2,17). In the BDL rat model, the 
proliferation of cholangiocytes and the reorganization of the 
hepatic microvasculature occur according to a well-defined 
timetable. In fact, one week after BDL, the number of bile 
ducts increases, particularly at the edges of portal tracts. 
At this time-period, cholangiocytes appear to markedly 
proliferate. In this phase, the hepatic microcirculation is 
poorly changed (17,20,22,23). After two weeks, proliferation 
of bile ducts continues and bile ducts are characterized 
by a dilated lumen and lined by cholangiocytes resting 
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on a basement membrane. At this stage, there is an active 
reorganization of the PBP that follows the proliferation 
of the bile ducts (20,45). After four weeks, the abundant 
proliferation of bile ducts is accompanied by septa of 
connective tissue located on the edge of the liver lobules. 
By means of vascular corrosion casts observed by scanning 
electron microscope (46) is possible to see a PBP that extends 
around the lobules and appears to be formed by homogeneous 
capillaries widely distributed that originate from arterioles 
arising from branches of the hepatic artery (20).
The evaluation of the molecular mechanisms that 
regulate the “typical” proliferation of cholangiocytes in 
BDL rats was made possible by the development of in vitro 
models such as the isolation and characterization of small 
and large cholangiocytes or intrahepatic bile duct units 
(IBDU) (2,5,7,30,37). The isolation of cholangiocytes 
from livers of normal or cholestatic rats is achieved 
through separation techniques based on immunoaffinity, 
i.e. through the use of antibodies expressed on the surface 
of all intrahepatic cholangiocytes (2,7). The isolation and 
study of IBDU of different sizes is essential for the direct 
assessment of the proliferative capacity of bile ducts. These 
units retain the morphological, phenotypic and functional 
characteristics of the intrahepatic bile ducts in situ (2,7). 
These tools have allowed us to define the morphologic and 
functional heterogeneity of intrahepatic bile ducts in normal 
and pathophysiological states. For example, after BDL 
large (but not small) cholangiocytes proliferate through 
the activation of cAMP-dependent signaling, leading to 
enhanced intrahepatic bile duct mass by activation of cAMP 
signaling (2,39,47). Also, cAMP induces cholangiocyte 
proliferation in association with increased activity of protein 
kinase A (PKA) and phosphorylation of Src-Tyrosine 139 
and ERK1/2 (48). This signaling cascade is also activated 
by factors such as estrogens (49), nerve growth factor (50), 
and insulin-like growth factor-1 (IGF-1) (51). Conversely, 
serotonin decreases biliary hyperplasia in cholestatic rats by 
the inhibition of cAMP/PKA/Src/ERK1/2 signaling (52).
Regarding the function of small cholangiocytes, 
several studies have shown that the activation of D-myo-
inositol 1,4,5-triphosphate (IP3)/Ca
2+-dependent signaling 
regulates the function of these cells (53-56). Small mouse 
cholangiocytes proliferate after H1 histamine receptor stimulation 
by activation of the IP3/CaMK I/CREB pathway (53). Further, 
histamine stimulates the proliferation of small and large 
cholangiocytes by activation of both IP3/Ca
2+ and cAMP-
dependent signaling mechanisms, respectively (56). For 
example, a study has shown that activation of alpha[1]-
adrenergic receptors stimulate the growth of small mouse 
cholangiocytes via Ca2+-dependent activation of nuclear 
factor of activated T cells 2 and specificity protein 1 (54). 
A recent study has demonstrated the existence of a P2 
signaling axis along the length of the biliary tree with the 
“upstream” small cholangiocytes releasing ATP, which can 
serve as a paracrine signaling molecule to “downstream” 
large cholangiocytes stimulating Ca2+-dependent secretion (55). 
Following functional damage of large cholangiocytes by 
apoptosis (e.g., after treatment acute administration of 
CCl4 and chronic treatment with gamma-aminobutyric 
acid (GABA), small cholangiocytes de novo proliferate and 
replenish the damaged biliary tree by amplification of 
Ca2+-dependent signaling and de novo acquisition of large 
cholangiocyte phenotypes (34,39,57).
One of the functions of cholangiocytes in humans is 
to modify the composition of bile. The bile produced by 
hepatocytes is particularly rich in bile salts, glutathione, 
lipids, proteins and other organic compounds and its 
flowing into bile ducts allows cholangiocytes to change 
its composition through mechanisms of reabsorption 
and secretion (58,59). Cholangiocytes in the adult liver 
are quiescent (34,39), since they express factors such as 
cyclin dependent kinase inhibitors p27, bcl2 and BclxL 
that are responsible for this mitotically dormant state (60). 
However, in pathological states cholangiocytes become 
mitotically activated both in experimental cholestasis (e.g., 
BDL and A feeding) (4,35) and in human cholangiopathies 
such as PBC and PSC classified as “vanishing bile duct 
syndrome” (58,59). The evolution of these cholangiopathies 
is characterized by an initial balance between cholangiocyte 
apoptosis with reduction of the number of bile ducts and 
compensatory cholangiocyte proliferation. By contrast, the 
end stage is characterized by the collapse of the proliferative 
capacity of cholangiocytes, resulting in the reduction of 
the number of bile ducts (vanishing bile duct syndrome). 
In these cases the compensated (non-ductopenic) stages of 
disease are characterized by a similar rate of apoptosis and 
proliferation, whereas in the terminal ductopenic stages 
apoptosis predominates favoring the evolution toward 
ductopenia. Therefore, in these pathologic conditions, 
the mechanism of repair based on the proliferation of 
residual cholangiocytes is not sufficient to avoid the 
evolution toward ductopenia. In this case then, stimulation 
of cholangiocyte proliferation could be a strategy for the 
management of human ductopenic pathologies affecting 
the intrahepatic biliary tree. On the other hand, reduction 
of cholangiocytes proliferation can be considered as the 
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possible strategy for the management of pathologies 
characterized by uncontrolled proliferative conditions 
such as cholangiocarcinoma (61-63) and polycystic 
liver diseases (60,64,65). We know that progenitor cells 
are activated when injury is associated with impaired 
regeneration of the mature cell types involved (66,67). 
Several factors such as viruses and alcohol can cause acute 
and chronic human liver disease through damage and 
loss of hepatocytes and/or cholangiocytes. The degree of 
progenitor cell activation, and the number of intermediate 
hepatocytes is directly proportionate with the degree 
of inflammatory activity (67,68), and with the stage of 
the disease (67,69). This aspect indicates that the HPC 
compartment activation is linked with the evolution of 
the disease. At the ductopenic stage of cholangiopathies, 
the functionality of bile ducts is strongly altered due to the 
change in bile flow and subsequent biliary stasis (58,59). 
Therefore, the fine regulation of secretion and proliferation 
of cholangiocytes is critical for the normal and physiological 
function of the liver. These aspects are influenced and 
controlled by many factors, including bile acids, autonomic 
nervous system, neuroendocrine substances, growth factors 
and hormones (Figure 1).
Regulation of cholangiocyte function and 
proliferation by hormones and neuropeptides
Sex hormones
Sex steroid hormones are able to influence the development 
Increased growth
Estrogen
IGF-1
Progesterone
Acetylcholine
Histamine-H1HR and H2HR
Substance P
VEGFs
FSH
Testosterone
Prolactin
Decreased growth
Gastrin
Somatostatin
Histamine-H3HR and H4HR
Melatonin
Serotonin
α-CGRP
TNF-α
GABA
Biliary tree
Proliferating cholangiocytes
Cholestasis
Biliary tree
Figure 1 Schematic illustration of the neuroendocrine compartment. Top. Immunohistochemistry for CK19, a specific marker of biliary 
epithelium in liver section from normal rat. Bar =40 μm. In normal condition cholangiocytes are quiescent (black arrows) but since they 
are target cells in several chronic cholestatic liver diseases (termed cholangiopathies), they start to proliferate as happen for example in the 
experimental model of bile ducts ligation (bottom. Immunohistochemistry for CK19 in liver section from BDL rat in which is evident the 
high proliferation of the biliary ducts (black arrows). Bar =40 μm. Proliferating cholangiocytes acquire the phenotype of neuroendocrine 
cells, and start to secrete different cytokines, growth factors, neuropeptides, and hormones to modulate cholangiocytes proliferation (on the 
right in red) or apoptosis (on the left in green) trying to reestablish the balance between proliferation/loss of cholangiocytes.
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and course of chronic liver diseases (70,71). It has been 
shown that cholangiocytes are estrogen-sensitive cells able 
to express both the estrogen receptors (ER-α and ER-β) 
in contrast to hepatocytes that express only the receptor 
ER-α (45). Our findings have shown that liver expresses 
estrogen and androgen receptors and experimentally both 
androgens and estrogens have been implicated in stimulating 
cell proliferation. Specifically, estrogens stimulate both in 
vitro and in vivo cholangiocyte proliferation and ERs may 
modulate cholangiocyte proliferation. In fact cholangiocyte 
proliferation, after 3 weeks of BDL, is associated with 
increased expression of both ER-α and ER-β (45,49,72). 
When tamoxifen (anti-estrogen) or ICI 182,780, a specific 
ER antagonist, were used to treat BDL rats, the intrahepatic 
bile duct mass markedly decreases in comparison with control 
BDL rats (45). These data were confirmed by ovariectomy of 
which effects reduce cholangiocyte proliferation in BDL (72). 
In vitro experiments showed that 17β-estradiol induces 
cholangiocytes proliferation by activation of the ER/Src/
Shc/ERK1/2 pathway (49). In humans, it has been shown 
that at late stages of PBC (73) the biliary expression of ER is 
decreased and ER-α positivity in cholangiocytes is markedly 
lower than that of cholangiocytes in primary sclerosing 
cholangitis and alcoholic cirrhosis (73). It has been shown 
that the low expression of ER-α in late stages of PBC 
promotes the development of PBC toward ductopenia (73). 
The relevance of estrogens in sustaining biliary growth is also 
supported by the fact that in middle-aged women (mainly 
affected by PBC), estrogen and progesterone levels are 
decreased (74,75).
In patients with cholangiocarcinoma (CCA) the expression 
of ER-α is higher than in normal condition, whereas a similar 
expression of ER-β was observed (73,76). In ovary, prostate, 
colon, and breast cancers it has been shown that, neoplastic 
transformation and tumor progression is associated with 
upregulation of ER-α and downregulation of ER-β (77,78). 
These data confirm the hypothesis that ER-α promotes cell 
proliferation whereas the opposite is observed for ER-β (77-79).
Similarly, testosterone is important in sustaining biliary 
proliferation and ductal secretory activity in pathological 
conditions associated with functional damage of the 
biliary epithelium (80). Specifically, we demonstrated 
that: (I) cholangiocytes express testosterone receptors, 
17β-hydroxysteroid-dehydrogenase3 (HSD3, the key 
enzyme regulating testosterone synthesis), and secrete 
testosterone; (II) castration influences the biliary growth 
in normal and BDL rats decreasing bile duct mass and 
secretin-stimulated cAMP levels, effects that were prevented 
by the exogenous administration of testosterone (80); These 
data suggest an autocrine role of testosterone in sustaining 
cholangiocyte proliferation during cholestasis. Parallel to 
these findings, other studies have shown the presence of 
functional ARs in liver cells, including hepatocytes and bile 
ducts from PBC patients (81). In particular, the expression 
of androgen receptors (ARs) was low in normal patients 
and increased in patients with PBC (81). The fact that 
testosterone prevents the loss of biliary growth and function 
supports the concept that androgens can be important for 
the management of ductopenic conditions associated with 
decreased testosterone levels as occurs in PBC (80). There 
is limited information regarding the role of progesterone 
in the regulation of biliary functions. We have recently 
demonstrated that: (I) progesterone stimulates proliferation 
of both male and female cholangiocytes (82); and (II) 
normal and BDL cholangiocytes expressed the biosynthetic 
pathway (i.e., steroidogenic acute regulatory protein or 
STAR, M3β-Hydroxysteroid dehydrogenase (M3β-HSD), 
and cytochrome P450 side-chain cleavage) for the synthesis of 
progesterone and secrete progesterone (82). These findings 
support the concept that endocrine, autocrine and paracrine 
mechanisms play an important role as compensatory 
mechanism for bile duct loss during cholangiopathies (73).
Cholangiocytes also express the long and short form of 
prolactin receptor (83). Also, chronic in vivo administration 
of prolactin to normal rats increases cholangiocyte 
proliferation and intrahepatic ductal mass (83). The 
proliferative effect of prolactin is associated with the 
activation of the IP3/Ca
2+/PKC/Src/MAPK pathway and the 
phosphorylation of the JAK2/STAT5 signalling pathway (83). 
These findings demonstrate the ability of proliferating 
cholangiocytes to secrete prolactin, thus regulating their 
own proliferation by an autocrine loop. 
Follicle stimulating hormone (FSH) is produced in the 
anterior pituitary gland of the brain (84). Several studies 
demonstrated that liver cirrhosis is associated with endocrine 
dysfunction, notably in the gonadal axis (85). In fact, 
gonadotropin deficiency occurs with liver damage and in 
some patients with hemochromatosis (86). We found that 
cholangiocytes expressed the FSH receptor (FSHR) and 
secreted FSH (86). Treatment of normal rats with FSH 
increases cholangiocyte growth via cAMP/ERK1/2/Elk-1 
signalling mechanism, whereas administration of antide (a 
gonadotropin releasing hormone antagonist that blocks FSH 
secretion) or an anti-FSH antibody decreases cholangiocyte 
proliferation and ductal secretory responses (87).
Moreover, other hormones and growth factors cross 
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talk together in normal and pathologic conditions. Indeed, 
the IGF1 has been shown to regulate cholangiocytes 
proliferation. In fact, the IGF1 is a circulating peptide 
(of which the liver is the main source of production) that 
acts locally as a growth factor with multiple endocrine, 
paracrine and autocrine functions (51,88,89). The IGF1 
is synthesized by the liver under the control of pituitary 
GH (Growth Hormone) which is tied to specific receptors 
(GH-R), induces the synthesis and release of circulating 
IGF-1 that play a key role in postnatal growth of many 
organs. Therefore, in cholangiocytes there is a complex 
interaction between estrogen and IGF1, which together are 
involved in the modulation of proliferation, apoptosis and cell 
differentiation promoting the processes of tissue repair (51,90).
Secretin
Secretin is one of the main factors responsible of the 
regulation of biliary secretion (4,8). Specifically, in normal 
rodents, secretin stimulates ductal secretion in large 
cholangiocytes (the only cholangiocyte subpopulation that 
expresses secretin receptor) (2,5,7,30). The interaction of 
secretin with the specific receptor determines the activation 
of the enzyme, adenylyl cyclase, with a consequent 
increase in the synthesis of cAMP capable of acting on 
PKA. Phosphorylation of PKA leads to the opening of the 
chloride channel, CFTR, and subsequently the activation 
of the ion pump Cl-/HCO3
- with secretion of HCO3
- and, 
for osmotic gradient, H2O (28,31). In pathologic conditions 
of cholangiocyte hyperplasia there is enhanced secretin 
receptor expression (2,31,32) and secretin-stimulated cAMP 
PKA/CFTR/Cl-/HCO3
- (2), leading to enhanced bicarbonate 
secretion in ductal bile (32). Instead in case of damage of 
large bile ducts there is decreased proliferation and down-
regulation of secretin and secretin-stimulated pathway, with 
decreased bicarbonate secretion in bile (39,57). Secretin 
has also been shown to stimulate biliary proliferation both 
in vivo and in vitro models (29). On the contrary, secretin 
has been shown to inhibit cholangiocarcinoma growth 
both in vitro in cholangiocarcinoma cells and in vivo in 
athymic mice (91). The inhibitory effects of secretin on 
cholangiocarcinoma growth via dysregulation of the cAMP-
dependent signaling mechanisms of the secretin receptor 
that coupled to Galpha(i) rather than Galpha(s) (91).
Gastrin
Gastrin, by interacting with its receptor cholecystokinin-B 
(CCK-B) located in the basolateral  membrane of 
cholangiocytes, gastrin inhibits secretin-stimulated 
cAMP levels and bile secretion (4) by downregulation 
of cAMP signaling (92). Gastrin has also been shown to 
inhibit cholangiocyte hyperplasia in cholestatic rats and 
cholangiocarcinoma growth by Ca2+-dependent activation 
of protein kinase C-alpha (47,93).
Somatostatin
Rat and human cholangiocytes as well as cholangiocarcinoma 
cell lines express somatostatin receptor subtypes, SSTR2 (4,94). 
Somatostatin has been shown to inhibit secretin-induced 
ductal hypercholeresis and exocytosis by interacting 
with SSTR2 on cholangiocytes by downregulation of 
cAMP levels (94). Somatostatin by selectively interacting 
with SSTR2 receptors inhibits the proliferation of large 
cholangiocytes in BDL rats by decreasing intracellular 
cAMP levels (2). Somatostatin and its analogues also 
inhibit the growth of human cholangiocarcinoma cell lines 
expressing SSTR2 receptor subtypes (95).
Histamine
Recent studies showed that small and large cholangiocytes 
express H1-H4HRs. Histamine and the H1HR agonist 
increased small bile duct mass, whereas histamine and the 
H2HR agonist increased large bile duct mass. H1HR agonists 
stimulated IP3 levels, as well as PKCα phosphorylation 
and cholangiocytes proliferation, whereas H2HR agonists 
increased cAMP levels, as well as PKA phosphorylation 
and cholangiocytes proliferation (56). Agonists of H1HR 
stimulate small (but not large) cholangiocyte proliferation 
by activation of IP3/CaMK I/CREB signaling (53). Indeed, 
activation of H3HR induces inhibition of large biliary 
growth of BDL rats by down-regulation of the cAMP-
dependent PKA/ERK1,2/Elk1 pathway (96).
I t  h a s  b e e n  s h o w n  t h a t  h i s t a m i n e  i n c r e a s e s 
cholangiocarcinoma growth by an autocrine mechanism, 
and that the inhibition of H1HR and of histamine synthesis 
by blocking his precursor histidine decarboxylase (HDC) 
significantly decreases cholangiocarcinoma growth (97).
Melatonin
Melatonin is secreted from pineal gland as well as 
extrapineal tissues; it regulates cell mitosis by interacting 
with melatonin receptors (MT1 and MT2) by modulating 
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cAMP and clock genes expression. In fact, in recent studies 
we have shown that cholangiocytes express MT1 and MT2 
receptors, and clock genes such as Circadian Locomotor 
Output Cycles Kaput (CLOCK), Aryl hydrocarbon 
receptor nuclear translocator-like (ARNTL or BMAL1), 
cryptochrome 1 (CRY1), and Period circadian protein 1 
(PER1) that were all up-regulated following BDL. Both 
in vivo and in vitro, melatonin decreased cholangiocytes 
proliferation in cholestatic rats by reducing the expression 
of clock genes by downregulation of cAMP levels and 
PKA phosphorylation in cholangiocytes (98). In the liver, 
melatonin has been shown to reduce oxidative damage 
and hepatic proliferation, and to stimulate apoptosis of 
hepatocytes in rats undergoing partial hepatectomy (99). 
Other studies have shown that melatonin ameliorates liver 
fibrosis (100), and reduces BDL-induced systemic oxidative 
stress in cholestatic rats (101).
In CCA there is  dysregulation of aralkylamine 
N-acetyltransferase (AANAT)/N-Acetylserotonin-O-
methyltransferase (ASMT) (key enzymes regulating 
melatonin secretion) → melatonin → melatonin receptor 
axis, which inhibited melatonin secretion and subsequently 
enhanced CCA growth (102). 
Growth factors and cytokines
A number of studies have shown that epidermal growth 
factor (EGF), hepatocyte growth factor (HGF), IGF1, 
interleukina-6 (IL-6), interleukin-1α, tumor necrosis 
factor α (TNF-α) and Vascular Endothelial Growth 
Factor (VEGF) stimulate both in vitro  and in vivo 
cholangiocyte proliferation (27,51,103). In particular 
about VEGF it has been shown that cholangiocytes 
secrete VEGF and express VEGFR-2 and VEGFR-3, all 
of which are amplified in BDL cholangiocytes. VEGF 
induces cholangiocyte proliferation by activation of IP3/
[Ca2+]I/protein kinase C alpha and phosphorylation of 
Src/ERK1/2 and it mediates the adaptive proliferative 
response of cholangiocytes to cholestasis via autocrine 
and paracrine mechanisms (22).
Neuropeptides
Several studies have shown that cholinergic, adrenergic 
and dopaminergic nerve fibers modulate cholangiocytes 
functions (104). It has been recently shown that cholangiocyte 
proliferation is positively modulated by parasympathetic 
and sympathetic innervation but negatively modulated by 
the serotoninergic system. Acetylcholine by acting on M3 
subtype receptor expressed by cholangiocytes, promote 
proliferative and secretory activities of cholangiocytes (3). 
In support of these data it has been shown that vagotomy 
induces the disappearance of M3 acetylcholine receptor 
in BDL but not in normal rats, reducing cholangiocyte 
proliferation, and activating apoptotic cell death together 
with decreased cAMP intracellular levels (3). Maintenance 
of cAMP levels by forskolin prevented the vagotomy-induced 
biliary damage (3).
Adrenergic  innervat ion a l so  regulates  hepat ic 
proliferation. It has been shown that proliferating 
cholangiocytes in BDL rats express α1 and α2 adrenergic 
receptors (19). Adrenergic innervation affects cholangiocytes 
proliferation by modulating intracellular levels of cAMP, 
as demonstrated by the chemical sympathetic denervation 
of the liver by 6-hydroxydopamine (6-OHDA). In fact the 
treatment with 6-OHDA increased cholangiocyte apoptosis 
and decreased cholangiocyte proliferation in association 
with decreased cAMP levels, and reduced phosphorylation 
of PKA, ERK1/2, and AKT (19). The changes induced by 
6-OHDA in cholangiocyte proliferation were prevented 
by dobutamine a β1 adrenergic receptor agonist, and 
clenbuterol a β2 adrenergic receptor agonist (19). 6-OHDA 
induced effects on biliary hyperplasia were also prevented 
by taurocholic acid feeding (105), a finding that suggests 
that bile acids may influence the proliferation of bile ducts. 
In fact, cholangiocytes in BDL rat are very sensitive to 
variations in composition of bile salts. It has been shown 
that while litocholate, taurocholate and taurolitocholate 
favor the proliferation of cholangiocytes, ursodeoxycholate 
and tauroursodeoxycholate inhibit proliferation (106). 
Cholangiocytes also express D2 dopamine receptor, whose 
activation by quinelorane induces inhibition of secretin-
stimulated choleresis by increased PKC-gamma expression 
and decrease of PKA activity (107).
Recently, we have shown that cholangiocytes express 
the serotonin 1A and 1B receptors (52). Their activation 
inhibits the growth of the intrahepatic biliary tree in 
the BDL model, by activation of the IP3/Ca
2+/PKC 
signaling pathway. Cholangiocytes are able to secrete 
serotonin, neutralization of which enhances cholangiocyte 
proliferation in the course of cholestasis (52).
Also, sensory innervation may regulate the hyperplasia 
of the biliary epithelium in cholestatic states (108). In fact 
high levels of the sensory neuropeptide α-CGRP promote 
biliary hyperplasia in the BDL cholestatic model. In vitro, 
both α and β-CGRP increased biliary proliferation by the 
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activation of cAMP-dependent PKA (108).
A recent study has also established that cholangiocytes 
express the neurokinin-1 receptor (NK-1R) which 
expression is up-regulated following BDL. In vitro, 
Substance P, a member of the tachykinin peptide 
family, increases cAMP levels, proliferation, and PKA 
phosphorylation of cholangiocytes (109).
Also, we demonstrated that GABA has heterogeneous 
effects on the apoptotic, proliferative, and secretory 
functions of small and large cholangiocytes in BDL rats. 
In fact we showed that chronic administration of GABA 
to BDL rats: induces apoptosis, reduces proliferation 
and decreases Ca2+-dependent adenylyl cyclase 8 (AC8) 
expression and secretin-stimulated choleresis in large 
cholangiocytes. Instead after GABA administration: small 
cholangiocytes de novo proliferate leading to an increased 
number of small ducts; show membrane translocation and 
phosphorylation of Ca2+-dependent PKCβII; and de novo 
express SR, CFTR, Cl-/HCO3
- and AC8, and secrete water 
and electrolytes in response to secretin. During damage of 
large cholangiocytes, small ducts replenish the intrahepatic 
biliary tree by amplification of both Ca2+-dependent 
signaling and the acquisition of large cholangiocyte 
phenotypes (57). 
Conclusions
In conclusion, as widely demonstrated, during chronic liver 
diseases, cholangiocytes are not quiescent but strongly 
activated cells constituting a neuroendocrine compartment, 
which is regulated by several and different factors including 
hormones, neuropeptides, cytokines, and growth factors. 
This neuroendocrine compartment produces and secretes 
several factors through which it regulates its own function 
and proliferation and also those of cells, which constitute 
the surrounding environment. Understand how to manage 
the neuroendocrine compartment and the several factors 
that this compartment is able to produce and secrete can 
be very important for the comprehension of progression of 
cholestatic liver diseases.
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